Form 4: Emergent BioSolutions Executive Receives RSU Grant

SVP and General Counsel Jessica Perl was granted 104,282 restricted stock units following shareholder approval of the company's incentive plan.

Summary

• Jessica Perl, SVP, General Counsel, and Corporate Secretary of Emergent BioSolutions, acquired 104,282 restricted stock units (RSUs).
• The grant was originally approved by the Compensation Committee on March 2, 2026, contingent upon shareholder approval of the Amended Stock Incentive Plan.
• Shareholders approved the plan on April 29, 2026, triggering the formal issuance of the units.
• The RSUs vest in three equal annual installments, subject to continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of executive compensation with long-term shareholder interests through equity-based incentives.
• Successful shareholder approval of the Amended Stock Incentive Plan, providing the company with necessary tools for talent retention.

Negatives

• Issuance of 104,282 RSUs results in potential future dilution for existing shareholders.

Risks

• Continued service requirement for vesting creates dependency on executive retention.
• Market volatility could impact the ultimate value of the equity compensation granted to the executive.

Future Outlook

The RSUs are set to vest in three annual installments, contingent upon the executive's continued service with the company.

Management Comments

• The grant is subject to the terms of the Amended Stock Incentive Plan and the specific grant agreement.

Industry Context

StockSavvy.ai notes that equity-based compensation remains a standard practice in the biotechnology sector to align executive incentives with long-term corporate performance and shareholder value.

Comparison to Industry Standards

• The use of three-year vesting schedules for RSUs is consistent with standard corporate governance practices for executive compensation in the U.S. biotech industry.
• The reliance on shareholder approval for incentive plan amendments aligns with best practices for transparency and governance.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for minor dilution upon the eventual vesting and conversion of RSUs into common stock.

Next Steps

• Vesting of the first installment of RSUs on the first anniversary of the approval date.

Key Dates

Keywords

Emergent BioSolutions, EBS, Form 4, Executive Compensation, Restricted Stock Units, Insider Transaction